Novo Nordisk remains coy over Wegovy blockbuster potential
Sales of Novo Nordisk’s newest obesity treatment, Wegovy, have been steadily increasing since its summer launch. Despite this, Novo CEO Lars Fruergaard Jørgensen remains silent on the drug’s blockbuster potential.
by christopher due karlsson, translated by daniel pedersen
With last Friday’s release of Novo Nordisk’s quarterly report for 2021, the pharmaceutical firm chose to reveal the actual sales figures for obesity drug Wegovy for the first time.